6533b82cfe1ef96bd128f58e

RESEARCH PRODUCT

Letter by Barco et al Regarding Article, "Restarting Anticoagulant Therapy After Intracranial Hemorrhage: A Systematic Review and Meta-Analysis"

Francesco DentaliFrederikus A. KlokBarco Stefano

subject

medicine.medical_specialtymedicine.drug_class030204 cardiovascular system & hematologyLower risk03 medical and health sciences0302 clinical medicinemedicineHumanscardiovascular diseasesIntensive care medicineStrokeAdvanced and Specialized NursingHumans; Anticoagulants; Intracranial HemorrhagesTreatment regimenbusiness.industryAnticoagulantAnticoagulantsmedicine.diseaseCausalitynervous system diseasesSurgeryAnticoagulant therapyMeta-analysisNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessIntracranial Hemorrhages030217 neurology & neurosurgeryRetrospective design

description

We read with interest the systematic review and meta-analysis authored by Murthy et al1 that appeared in Stroke . The authors studied the efficacy and safety of anticoagulant resumption after nontraumatic intracranial hemorrhage (ICH) and showed that resumption was associated with a lower risk of arterial thromboembolism but a similar risk of recurrent ICH. We do have some comments on their interpretation of the results. First, all the included studies had a retrospective design and, therefore, are characterized by heterogeneity in treatment regimens and timing of anticoagulation restart. As the authors argue in their discussion, location matters for the risk of recurrent ICH: lobar bleedings are more prone to rebleeding than nonlobar bleedings. The authors could not control for this or other sources of heterogeneity by adjustment, stratification, or matching: therefore, any interpretation of causality warrants caution …

https://hdl.handle.net/1887/95973